Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients.

Although renal osteodystrophy and vitamin D analogs may be related to survival in maintenance hemodialysis (MHD) patients, most studies have examined associations between baseline values and survival without accounting for variations in clinical and laboratory measures over time. We examined associations between survival and quarterly laboratory values and administered paricalcitol in a 2-year (July 2001-June 2003) cohort of 58,058 MHD patients from all DaVita dialysis clinics in USA using both time-dependent Cox models with repeated measures and fixed-covariate Cox models with only baseline values. Whereas hypercalcemia and hyperphosphatemia were robust predictors of higher death risk in all models, the association between serum calcium and mortality was different in time-varying models. Changes in baseline calcium and phosphorus values beyond the Kidney Disease Outcome Quality Initiative recommended targets were associated with increased mortality. Associations between high serum parathyroid hormone and increased death risk were masked by case-mix characteristics of MHD patients. Time-varying serum alkaline phosphatase had an incremental association with mortality. Administration of any dose of paricalcitol was associated with improved survival in time-varying models. Controlling for nutritional markers may introduce overadjustment bias owing to their strong collinearity with osteodystrophy surrogates. Whereas both time-dependent and fixed-covariate Cox models result in similar associations between osteodystrophy indicators and survival, subtle but potentially clinically relevant differences between the two models exist, probably because fixed models do not account for variations of osteodystrophy indices and changes in medication dose over time.

[1]  K. Martin,et al.  Vitamin D analogs: actions and role in the treatment of secondary hyperparathyroidism. , 2004, Seminars in nephrology.

[2]  F. Port,et al.  Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. , 2005, Kidney international.

[3]  Sander Greenland,et al.  Multiple‐bias modelling for analysis of observational data , 2005 .

[4]  Grace H. Lee,et al.  Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  F. Locatelli,et al.  Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. , 2004, The New England journal of medicine.

[6]  C. Zoccali,et al.  Low parathyroid hormone and pentosidine in hemodialysis patients. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  J. Bergström,et al.  High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  F. Port,et al.  Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  R. Foley,et al.  Hypocalcemia, morbidity, and mortality in end-stage renal disease. , 1996, American journal of nephrology.

[10]  P. Fein,et al.  Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  G. Chertow,et al.  Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. , 2004, Journal of the American Society of Nephrology : JASN.

[12]  R. Elashoff,et al.  Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. , 2005, Journal of the American Society of Nephrology : JASN.

[13]  R. Foley,et al.  Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease. , 1996, Journal of the American Society of Nephrology : JASN.

[14]  S. Greenland,et al.  Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  K. Kalantar-Zadeh,et al.  Normalized protein nitrogen appearance is correlated with hospitalization and mortality in hemodialysis patients with Kt/V greater than 1.20. , 2003, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

[16]  D. Scharfstein,et al.  Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients. , 2004, Journal of clinical epidemiology.

[17]  Takashi Akiba,et al.  Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[18]  G. Eknoyan,et al.  Bone metabolism and disease in chronic kidney disease , 2003 .

[19]  N. Powe,et al.  Validation of comorbid conditions on the end-stage renal disease medical evidence report: the CHOICE study. Choices for Healthy Outcomes in Caring for ESRD. , 2000, Journal of the American Society of Nephrology : JASN.

[20]  S. Greenland,et al.  Kalantar-Zadeh, K. et al. Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction. Nephrol. Dial. Transplant. 20, 1880-1888 , 2005 .

[21]  F. Kronenberg,et al.  Prevalence and progression of peripheral arterial calcifications in patients with ESRD. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  S. Greenland,et al.  Reverse Epidemiology of Hypertension and Cardiovascular Death in the Hemodialysis Population: The 58th Annual Fall Conference and Scientific Sessions , 2005, Hypertension.

[23]  S. Greenland,et al.  Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[24]  B. Leistikow Commentary: Questionable premises, overadjustment, and a smoking/suicide association in younger adult men. , 2003, International journal of epidemiology.

[25]  B. Kestenbaum,et al.  Serum phosphate levels and mortality risk among people with chronic kidney disease. , 2005, Journal of the American Society of Nephrology : JASN.

[26]  P. Raggi,et al.  Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. , 2002, Kidney international.

[27]  S. Massry,et al.  Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[28]  E. Slatopolsky,et al.  Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[29]  Ajay K. Singh,et al.  Complications of chronic kidney disease: anemia, mineral metabolism, and cardiovascular disease. , 2005, The Medical clinics of North America.

[30]  M. Marinella The refeeding syndrome and hypophosphatemia. , 2003, Nutrition reviews.

[31]  R. Foley,et al.  Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. , 2005, Journal of the American Society of Nephrology : JASN.

[32]  K. Kalantar-Zadeh,et al.  Time-dependent associations between iron and mortality in hemodialysis patients. , 2005, Journal of the American Society of Nephrology : JASN.

[33]  Brennan,et al.  Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. , 1987, Clinical chemistry.

[34]  S. Greenland,et al.  Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. , 2006, Journal of the American Society of Nephrology : JASN.

[35]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[36]  J. Kaufman,et al.  Epoetin requirements predict mortality in hemodialysis patients. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[37]  G. Kaysen,et al.  Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[38]  J T Daugirdas,et al.  The post: pre dialysis plasma urea nitrogen ratio to estimate K.t/V and NPCR: validation. , 1989, The International journal of artificial organs.

[39]  D. Andress VITAMIN D IN HEALTH AND DISEASE: Vitamin D Treatment in Chronic Kidney Disease , 2005, Seminars in dialysis.

[40]  P. Raggi,et al.  Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? , 2002, Journal of the American College of Cardiology.

[41]  Keith C. Norris,et al.  K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[42]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[43]  M. Hernán,et al.  Activated injectable vitamin D and hemodialysis survival: a historical cohort study. , 2005, Journal of the American Society of Nephrology : JASN.

[44]  K. Kalantar-Zadeh,et al.  Clinical characteristics and mortality in hepatitis C-positive haemodialysis patients: a population based study. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[45]  Keith C. Norris,et al.  Clinical and laboratory features of aluminum-related bone disease: differences between sporadic and "epidemic" forms of the syndrome. , 1985, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[46]  P. Stenvinkel,et al.  Why Do Dialysis Patients Develop a Heart of Stone and Bone of China? , 2005, Blood Purification.